Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. - Wikidata - awgldk - TriplyDB

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

http://www.wikidata.org/entity/Q54456791

about

Treatment of inflammatory myopathy: emerging therapies and therapeutic targets Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease Evaluation of muscles affected by myositis using magnetic resonance elastography.Idiopathic inflammatory myopathies.Cutaneous dermatomyositis in the era of biologicals.Pathogenesis of dermatomyositis: role of cytokines and interferon.Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis.Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases.Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases.Type I interferon pathway in adult and juvenile dermatomyositis.Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity Resistin in idiopathic inflammatory myopathies.Beyond the MHC: A canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci.Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.Phenotypes of Peripheral Blood Lymphocytes and Cytokine Expression in Polymyositis and Dermatomyositis before Treatment and after Clinical Remission.Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course Aberrant expression of cytokine interleukin 9 along with interleukin 4 and interferon γ in connective tissue disease-associated interstitial lung disease: association with severity of pulmonary fibrosis.Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients Consensus-based recommendations for the management of juvenile dermatomyositis.Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Immunotherapeutic implication of IL-6 blockade.Targeted immunotherapy trials for idiopathic inflammatory myopathies.Gene expression and regulation in systemic lupus erythematosus.Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.Immunological biomarkers in dermatomyositis.

P2860

Q26796546-6E450126-DC06-4ED8-BBEF-74FCA08A4A64 Q26798209-36A7FBE9-25C8-4261-BE9F-84EEA1D5AAE8 Q28290930-A16473CC-E733-4974-8AEC-43CA26A96B8C Q28652726-79BB7851-DFA8-406F-841A-BF3762C6D1F4 Q30469107-86707445-CC0A-42B6-B73D-207F03A985B0 Q33924451-CED2D7D7-D24D-4F6E-A690-E9223F7B818B Q34501531-CFD0B8DD-0AF1-4622-8667-0F9B8FBEFCE2 Q34626955-F6600DC1-3411-4590-A78D-50BD6FF95A4B Q35112489-1BF261E5-5FC4-429D-9054-385E4708ECA2 Q35125063-69D6EA0C-A74E-482C-9EC9-8A1481601465 Q35724900-99BC24B7-6868-4EBA-9E1E-18A7A17F8B00 Q35838076-110A75C2-96E2-4A60-8B2B-C2B039B204DB Q35861492-7A89A382-C05B-4E18-A4B8-51A85AE0563B Q35907790-F9AB7634-4163-4189-A021-8772ED54F30C Q36108080-0F226AC9-5074-4326-B84B-7C2780997C57 Q36245680-8DC20D3B-1F51-438C-A336-531B1E229C56 Q36245955-4D558D28-7A99-4687-A9F5-715D2F928230 Q36269554-EDDF0AF2-8ACF-4D6A-B52D-D11318E23801 Q36312962-EB0F6A51-EC98-4F51-8666-0ACC2A9CCD9D Q36346324-2B67D27D-A51B-4D7E-88C2-226E0D223050 Q36434501-6F237256-6A75-4CD0-93DC-19B4D559D6A7 Q36582317-1E9E6FA8-F54A-412A-BA07-47A15929F37A Q36942366-C9A9C6FD-0961-4B3B-B0CF-64A530A2EA04 Q37022721-23C15CB5-FF31-45E2-8B3E-A48E5EB52B9F Q37095730-3D5E10A8-EA8D-4E51-820A-B3ECFE4B8FD4 Q37316232-B2962791-A855-4DB6-8A83-BCBE9E8299BE Q37368405-5916BB03-68A2-4EB6-A8C9-08ED50D948B8 Q37465544-F0460AF5-16DA-4487-87C1-5DAA68A64C6D Q37617000-861F0AD2-903B-406D-8DBC-340A6E6C5593 Q37674711-EB4A0FFB-E28D-4E92-84C4-106275A2CB26 Q37689900-E3EDD8FF-FFDA-4A08-B22E-1FBFE7995ADD Q37825936-FA87268E-F754-4973-99D8-C72FFBEA5DB1 Q37906737-3E8A13E0-56B3-4E8A-B3CA-1EFC3683FB72 Q37938701-F4037BCD-24F0-460F-B0DF-05F2ED9C9715 Q37965754-CD9F8BBC-8A82-4B2D-B97A-2B968C3551CA Q38023207-A270D91F-9AC3-4EAC-B74A-D1E802D8C640 Q38125510-CFE5014A-2A52-4794-AE7B-3B5CC5E1CF2C Q38221095-B7430F4E-C435-43A7-9E29-BBC296D77E55 Q38244567-C337FEC5-C06A-466E-80F4-1B8AEF1BF0D6 Q38592676-93DBD57D-B3FD-4224-BA45-92010FB4A6B1

P2860

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

http://www.wikidata.org/entity/Q54456791

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@en

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@nl

type

label

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@en

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@nl

prefLabel

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@en

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@nl

P1433

Q54456791-2B2D9544-356A-48AF-BB97-8EE4E5D402EF

P1476

Q54456791-DBA01568-569C-484C-B003-2438519086AD

P2093

Q54456791-37C0BACF-692F-45C5-825F-DE64E2A55ED0

Q54456791-6BE24BC6-8E72-4EFA-9BBA-3CEC2BE53B34

Q54456791-76C2BF6A-4CA9-43D1-A878-C569D4F2F590

Q54456791-8A60CA0B-A83A-43F6-B620-CCCA209E11F9

Q54456791-98758142-C755-4698-9471-5FD942F154E7

Q54456791-9FF5E664-FBC5-49FB-A285-34E95667A602

Q54456791-A193F41D-AC55-4B7A-9C5C-0F83043E44BA

Q54456791-A1A322A7-8B04-42D3-8374-593B39C39574

Q54456791-DA86D215-1B08-4916-8B67-FBAB79F21372

Q54456791-E60D4B94-50BE-41F1-BABA-16C860FD8AE2

P2860

Q54456791-08C5043D-D85C-4B19-AE7E-E54C299200CD

Q54456791-0A1E7241-840F-4D87-9FB6-B5C25D52B281

Q54456791-0ACE5831-CB49-4FA4-88C0-6B71626649A9

Q54456791-0DD9E1E1-772C-4B89-8E97-DD644ED65ED2

Q54456791-109BB625-749D-42C0-9606-C6D2602B1ACA

Q54456791-1ED3D5A1-726C-4F31-B6C1-8596923736F5

Q54456791-20E7CC0B-0A35-4398-88B3-FA56E841A0A1

Q54456791-26EAA1C8-41D2-4D4E-97B9-4E4641DE694E

Q54456791-2EAD55A7-530A-401E-9B6B-6AA16742CDB5

Q54456791-2F6F004A-18A4-44C3-BE6B-5C2AC64C35F3

P304

Q54456791-88A650A8-5822-4CDA-B54F-027337D4C106

P31

Q54456791-CA70B6F1-D6CA-4F97-AAAD-120E03FA9AE3

P356

Q54456791-32DD8B54-6850-4AEF-ABDB-DD8D02240653

P433

Q54456791-0C28E1BA-06EC-46AC-A771-CE634BC20254

P478

Q54456791-BC400991-9525-4B28-BE71-17D9871FEE5A

P577

Q54456791-DFFA9727-857A-4E35-91C8-B500F1D0CDC3

P5875

Q54456791-79270285-92EC-44C1-B391-95532E48642E

P698

Q54456791-CC6C3B54-B621-4C27-BFEA-CBE8BF6C3E11

P921

Q54456791-5D4F3265-EF80-4EC8-93D6-F939E2C4E3F4

Q54456791-da2a55e6-49f8-4735-a7ed-4d526e00a5ee

P356

P1433

Arthritis and Rheumatism

P1476

Interleukin-6 and type I inter ...... e activity in dermatomyositis.

@en

P2093

Ann M Reed

http://www.w3.org/2001/XMLSchema#string

Brant Newman

http://www.w3.org/2001/XMLSchema#string

Emily C Baechler

http://www.w3.org/2001/XMLSchema#string

Erik J Peterson

http://www.w3.org/2001/XMLSchema#string

Hatice Bilgic

http://www.w3.org/2001/XMLSchema#string

Jason W Bauer

http://www.w3.org/2001/XMLSchema#string

Joseph C Wilson

http://www.w3.org/2001/XMLSchema#string

Kelly T McNallan

http://www.w3.org/2001/XMLSchema#string

Shreyasee Amin

http://www.w3.org/2001/XMLSchema#string

Sonja Ellingson

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

The nature of the principal type 1 interferon-producing cells in human blood

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis.

Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies

Update on the genetics of the idiopathic inflammatory myopathies.

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

P304

3436-3446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.24936

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38055460

http://www.w3.org/2001/XMLSchema#string

P698

19877033

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis